RIPK2 Protein, Human (P. pastoris, His)

RIPK2 is a multifunctional serine/threonine/tyrosine protein kinase that coordinates innate and adaptive immune responses. It is activated by bacterial peptidoglycan to form filaments in the NOD1 and NOD2 pathways, undergoing autophosphorylation and polyubiquitination. RIPK2 Protein, Human (P. pastoris, His) is the recombinant human-derived RIPK2 protein, expressed by P. pastoris , with C-6*His, C-6*His labeled tag. The total length of RIPK2 Protein, Human (P. pastoris, His) is 540 a.a., with molecular weight of 66 kDa.

RIPK2, a serine/threonine/tyrosine-protein kinase, plays a pivotal role in orchestrating innate and adaptive immune responses. As a key effector in NOD1 and NOD2 signaling pathways, RIPK2 forms filaments upon activation by bacterial peptidoglycans, recruited via CARD-CARD domains. Autophosphorylation and polyubiquitination follow, involving 'Lys-63'-linked ubiquitin chains by XIAP, BIRC2, and BIRC3, as well as 'Met-1'-linked polyubiquitination by the LUBAC complex. This transforms RIPK2 into a scaffolding protein, recruiting downstream effectors. 'Lys-63'-linked polyubiquitin chains on RIPK2 facilitate the recruitment of IKBKG/NEMO, initiating the activation of IKBKB/IKKB and subsequent NF-kappa-B release from inhibitors. While the kinase activity is dispensable for NOD1 and NOD2 pathways, RIPK2 contributes to tyrosine phosphorylation of ARHGEF2, activating NF-kappa-B through NOD2. Additionally, in adaptive immunity, RIPK2 promotes BCL10 phosphorylation during T-cell receptor engagement, and participates in RHOA inactivation in response to NGFR signaling. This multifaceted kinase stands as a crucial mediator in diverse immune processes.

Human

P. pastoris

C-6*His

O43353 (M1-M540)

8767  [NCBI]

MNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLKKTKLQSVSSAIHLCDKKKMELSLNIPVNHGPQEESCGSSQLHENSGSPETSRSLPAPQDNDFLSRKAQDCYFMKLHHCPGNHSWDSTISGSQRAAFCDHKTTPCSSAIINPLSTAGNSERLQPGIAQQWIQSKREDIVNQMTEACLNQSLDALLSRDLIMKEDYELVSTKPTRTSKVRQLLDTTDIQGEEFAKVIVQKLKDNKQMGLQPYPEILVVSRSPSLNLLQNKSM

Approximately 66 kDa

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.